

## **Role of Inflammation in Depressive and Anxiety Disorders, Affect, and Cognition: Genetic and Non-Genetic Findings in the Lifelines Cohort Study.**

### Authors

Naoise Mac Giollabhui<sup>+</sup>, Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General Hospital, USA.

Chloe Slaney<sup>+</sup>, MRC Integrative Epidemiology Unit at the University of Bristol, UK; Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK

Gibran Hemani, MRC Integrative Epidemiology Unit at the University of Bristol, UK

Éimear M. Foley, MRC Integrative Epidemiology Unit at the University of Bristol, UK; Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.

Peter J. van der Most, University of Groningen, University Medical Center Groningen, the Netherlands.

Ilja M. Nolte, University of Groningen, University Medical Center Groningen, the Netherlands.

Harold Snieder, University of Groningen, University Medical Center Groningen, the Netherlands.

George Davey Smith, MRC Integrative Epidemiology Unit at the University of Bristol, UK.

Golam Khandaker<sup>\*</sup>, MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol,

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

UK; NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK; Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.

Catharina A. Hartman<sup>\*</sup>, Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, University of Groningen, the Netherlands.

<sup>+</sup> = Equally contributing first author.

<sup>\*</sup> = Equally contributing senior author.

Corresponding authors: Please direct correspondence regarding non-genetic analyses to Naoise Mac Giollabhui (Depression Clinical & Research Program, 1 Bowdoin Square, Massachusetts General Hospital, Boston, MA, USA. E-mail: [nmacgiollabhui@mg.harvard.edu](mailto:nmacgiollabhui@mg.harvard.edu)) and correspondence regarding genetic analyses to Chloe Slaney (MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. E-mail: [chloe.slaney@bristol.ac.uk](mailto:chloe.slaney@bristol.ac.uk)).

Word count (excluding abstract): 5,375

**Keywords:** Depression; Anxiety; Affect; Cognition; Inflammation; CRP; Lifelines Cohort; Mendelian randomization.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

1 **Abstract**

2 **Background:** Low-grade systemic inflammation is implicated in the pathogenesis of various  
3 neuropsychiatric conditions affecting mood and cognition. While much of the evidence concerns  
4 depression, large-scale population studies of anxiety, affect, and cognitive function are scarce.  
5 Importantly, causality remains unclear. We used complementary non-genetic, genetic risk score  
6 (GRS), and Mendelian randomization (MR) analyses to examine whether inflammatory markers  
7 are associated with affect, depressive and anxiety disorders, and cognitive performance in the  
8 Lifelines Cohort; and whether associations are likely to be causal.

9 **Methods:** Using data from up to 55,098 (59% female) individuals from the Dutch Lifelines  
10 cohort, we tested the cross-sectional and longitudinal associations of C-reactive protein (CRP)  
11 with (i) depressive and anxiety disorders; (ii) positive and negative affect scores, and (iii) five  
12 cognitive measures assessing attention, psychomotor speed, episodic memory, and executive  
13 functioning (figural fluency and working memory). Additionally, we examined the association  
14 between inflammatory marker GRSs (CRP, interleukin-6 [IL-6], IL-6 receptor [IL-6R and  
15 soluble IL-6R (sIL-6R)], glycoprotein acetyls [GlycA]) on these same outcomes ( $N_{\max}=57,946$ ),  
16 followed by MR analysis examining evidence of causality of CRP on outcomes ( $N_{\max}=23,268$ ).  
17 In genetic analyses, all GRSs and outcomes were z-transformed.

18 **Results:** In non-genetic analyses, higher CRP was associated with diagnosis of any  
19 depressive disorder, lower positive and higher negative affect scores, and worse performance on  
20 tests of figural fluency, attention, and psychomotor speed after adjusting for potential  
21 confounders, although the magnitude of these associations was small. In genetic analyses,  
22  $CRP_{GRS}$  was associated with any anxiety disorder ( $\beta=0.002$ ,  $p=0.037$ ,  $N=57,047$ ) whereas  
23  $GlycA_{GRS}$  was associated with major depressive disorder ( $\beta=0.001$ ,  $p=0.036$ ;  $N=57,047$ ). Both

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

24 CRP<sub>GRS</sub> ( $\beta=0.006$ ,  $p=0.035$ ,  $N=57,946$ ) and GlycA<sub>GRS</sub> ( $\beta=0.006$ ,  $p=0.049$ ;  $N=57,946$ ) were  
25 associated with higher negative affect score. Inflammatory marker GRSs were not associated  
26 with cognitive performance, except sIL-6R<sub>GRS</sub> which was associated with poorer memory  
27 performance ( $\beta=-0.009$ ,  $p=0.018$ ,  $N=36,783$ ). Further examination of the CRP-anxiety  
28 association using MR provided some weak evidence of causality ( $\beta=0.12$ ;  $p=0.054$ ).

29 **Conclusions:** Genetic and non-genetic analyses provide consistent evidence for an  
30 association between CRP and negative affect. Genetic analyses suggest that IL-6 signaling could  
31 be relevant for memory, and that the association between CRP and anxiety disorders could be  
32 causal. These results suggest that dysregulated immune physiology may impact a broad range of  
33 trans-diagnostic affective symptoms. However, given the small effect sizes and multiple tests  
34 conducted, future studies are required to investigate whether effects are moderated by sub-groups  
35 and whether these findings replicate in other cohorts.

36

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

### 37 **1. Introduction**

38 Depression affects 300 million individuals worldwide at any given point in time and is the  
39 leading cause of mental health-related global disease burden (1-3). Persistent cognitive problems,  
40 such as poor memory and concentration, are reported in 11% of adults aged  $\geq 45$  years (4) and are  
41 frequently observed across a broad range of physical [cancer (35%); COVID-19 (22%); HIV  
42 (43%); hepatitis C (50%)] (5-8) and mental health conditions [depression (30%); schizophrenia  
43 (50%)] (9, 10). Existing treatments for depression are only modestly effective (11) and almost  
44 inexistent for cognitive dysfunction (12, 13). A mechanistic understanding of depression and  
45 cognitive dysfunction is urgently needed to inform the development of effective treatments and  
46 prevention approaches.

47 Chronic, low-grade systemic inflammation may represent one such mechanism. Indices of  
48 inflammation [e.g., circulating levels of cytokines (e.g., interleukin-6 (IL-6) and acute phase  
49 proteins (e.g., C-reactive protein (CRP))] are elevated in individuals with depression compared to  
50 controls (14) and inflammatory biomarkers have been linked to specific aspects of depression,  
51 such as anhedonia and negative affect (15-17). Further, longitudinal observational studies have  
52 found that higher levels of inflammatory biomarkers (e.g., IL-6, CRP) are prospectively  
53 associated with higher depressive symptoms (18). Observational studies have linked  
54 inflammation with impaired cognition in population-based (19-22) and in physical (5-9, 23-27)  
55 and mental health conditions (28-32). Inflammation also impacts neural circuitry relevant to  
56 affective disorder and cognitive task performance (33, 34), particularly the hippocampus (35)  
57 and striatum (36-39). To date, inflammation-cognition research has primarily relied upon  
58 observational data.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

59        Inferring causality from observational studies is a challenge due to confounding (e.g., stress,  
60 poor sleep (27)) and reverse causality (i.e., whether inflammation impacts depression/cognition,  
61 or vice versa). Mendelian randomization (MR) is a genetic epidemiological method that can test  
62 causal relationships by using genetic variants associated with an exposure (e.g., inflammation) as  
63 proxies for the exposure (40, 41). As genetic variants are randomly inherited from parents to  
64 offspring and are fixed at conception, they are less likely to be associated with confounders and  
65 overcome issues of reverse causation (40, 41). Preliminary evidence, using MR, implicate IL-6  
66 and its soluble IL-6 receptor (sIL-6R) in depression (42-45). To date, most MR studies  
67 examining the effect of IL-6 on health have focused on circulating IL-6 levels. However, IL-6  
68 signals via multiple pathways (trans-signaling, classical-signaling, and trans-presentation) and  
69 there is growing evidence that IL-6 trans-signaling is primarily responsible for the pathogenic  
70 inflammatory effects of IL-6 (46, 47). Here, we include variants related to (1) circulating IL-6  
71 levels, and (2) sIL-6R levels (relevant for IL-6 trans-signaling). Causal evidence for CRP and  
72 other proinflammatory markers [i.e., Glycoprotein Acetyls (GlycA) a composite biomarker  
73 thought to provide a more stable marker of inflammation which reflects the glycosylation of  
74 multiple acute-phase proteins (48-51)] on depression are mixed (42, 45, 52-55). Regarding  
75 cognition, few studies have examined potential causal relationships with inflammation. MR  
76 analyses using available genome-wide association studies (GWAS) report both null results of  
77 inflammatory biomarkers on emotion recognition, working memory, response inhibition (56) as  
78 well as effects of specific cytokines/chemokines (i.e., Eotaxin, IL-8, MCP1, IL-4) on fluid  
79 intelligence (57).

80        The current study used data from the Lifelines Cohort Study – a large population-based  
81 cohort in the Netherlands – to conduct complementary non-genetic and genetic analysis to

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

82 investigate the causal relationship between inflammation and negative affect, depressive  
83 disorders, and cognitive task performance. First, we used cross-sectional and longitudinal non-  
84 genetic analysis examine the association between circulating levels of CRP and  
85 depression/cognitive performance. Second, we conducted genetic risk score (GRS) and MR  
86 analysis to test whether genetic variants regulating levels and activity of CRP, IL-6, and GlycA  
87 were causally related with depression/cognitive performance. We also conducted the above  
88 analyses on closely related constructs (e.g., anxiety, negative/positive affect), for which  
89 associations with inflammation have previously been observed (58-63) but for which  
90 considerably less empirical data has been published. We hypothesized that both circulating CRP  
91 levels and genetically predicted inflammatory biomarkers (i.e., CRP, IL-6, sIL-6R, and GlycA)  
92 would be associated with depression, cognitive task performance, affect, and anxiety.

93

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

94

### **2. Methods and Materials**

95

#### **2.1 Participants**

96 Lifelines is a multi-disciplinary prospective population-based cohort study examining in a  
97 unique three-generation design the health and health-related behaviors of 167,729 persons living  
98 in the North of the Netherlands. It employs a broad range of investigative procedures in assessing  
99 the biomedical, socio-demographic, behavioral, physical and psychological factors which  
100 contribute to the health and disease of the general population, with a special focus on multi-  
101 morbidity and complex genetics (64). This cohort has previously been described in detail (64,  
102 65). In brief, participants were recruited via their general practitioner (49%), participating family  
103 members (38%), and self-registration on the Lifelines website (13%). Exclusion criteria for  
104 recruitment through the general practitioner included: insufficient knowledge of Dutch language,  
105 severe psychiatric or physical illness, limited life expectancy (<5 years). Baseline data included  
106 approximately: 140,000 adults (18-65 years), 15,000 children (0-17 years), 12,000 elderly  
107 individuals (65+ years). Following baseline assessment, participants are invited to complete an  
108 in-person study visit every 5 years (2<sup>nd</sup> in person follow-up assessment just finished end of  
109 2023). Phenotypic and genotypic data are collected by Lifelines to permit investigation on  
110 determinants of health. Data for the current study were drawn from 147,815 individuals who  
111 were aged 18+ years at baseline and who did not report a diagnosis that typically impairs  
112 cognitive function, specifically Alzheimer's disease, other dementias, epilepsy, multiple  
113 sclerosis, Parkinson's disease, and stroke. In the non-genetic analyses, the analytic sample is  
114 smaller as CRP was assessed in a sub-sample of individuals (N=55,098) as was baseline  
115 cognitive performance on the Ruff Figural Fluency Test (N=88,096). The analytic sample is  
116 smaller for non-genetic (N≤55,098), GRS (N≤57,946) and MR (N≤23,268) analysis as only a



## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

117 subset of participants who met inclusion criteria had outcome data and (i) CRP data (non-genetic  
118 analysis), (ii) genetic data (GRS), or (iii) genetic and CRP data (MR) due to time and cost  
119 constraints. Phenotypic data were drawn from both the baseline assessment and the first follow-  
120 up assessment; whether a specific measure was assessed at baseline, first follow-up or both  
121 assessments is noted for each measure.

### 122 **2.2 Measures**

#### 123 *2.2.1 Measures of Cognitive Task Performance*

124 *Ruff Figural Fluency Test (baseline in-person assessment).* The Ruff Figural Fluency Test  
125 (RFFT) is a reliable and valid measure of figural fluency, a dimension of executive function (66),  
126 measured at the baseline assessment. It is likely that performance on the RFFT also depends on  
127 other cognitive abilities, such as processing speed (67, 68). Participants were asked to draw as  
128 many unique designs as possible within 60 seconds by connecting dots in different patterns. The  
129 task is composed of five parts, with each part containing 35 identical five-dot patterns (with or  
130 without distractors). The total number of unique designs was used as the dependent variable in  
131 the analyses, consistent with previous studies (69, 70). In Lifelines, the RFFT was administered  
132 to all participants until April 2012, and subsequently in a random half of the sample. Data from  
133 participants who failed to generate a single unique design per trial ( $n = 181$ ) were deemed invalid  
134 and removed.

135 *Cogstate Test Battery (first follow-up in-person assessment).* Assessments included in the  
136 Cogstate Test Battery consisted of four tasks and took approximately 10-15 minutes to complete.  
137 Each task was designed to tap into specific cognitive domains: detection task (psychomotor  
138 speed), identification task (attention), one-back task (working memory), and one card learning

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

139 task (episodic memory), although, like in the RFFT, processing speed likely plays a role in all  
140 tasks. For each task, outcomes recommended by Cogstate were selected, specifically: log<sub>10</sub>  
141 transformed response time in millisecond (detection and identification tasks) and arcsine-  
142 transformed response accuracy (one-back and one card learning tasks). For the detection and  
143 identification tasks, higher values reflect poorer performance and for the one-back and one card  
144 learning tasks, higher values equal better performance. Data cleaning involved excluding  
145 participants with a high number of errors. The percentage of successful trials per Cogstate task  
146 was high, averaging 66% ( $n = 85,050$ ;  $SD = .11$ ) on the episodic memory task, 91% ( $n = 85,053$ ;  
147  $SD = .17$ ) on the visual attention task, 92% ( $n = 85,053$ ;  $SD = .20$ ) on the psychomotor speed  
148 task, and 90% ( $n = 85,051$ ;  $SD = .15$ ) on the working memory task. A small number of  
149 participants exhibiting implausibly low accuracy rates indicative of poor effort, failure to  
150 comprehend task instructions, or technical errors were excluded from analyses. Specifically  
151 individuals with an accuracy rate less than: 25% on the episodic memory task ( $n = 231$ ), 40% on  
152 the visual attention task ( $n = 2,878$ ), 45% on the psychomotor speed task ( $n = 3,914$ ), and 35%  
153 on the working memory task ( $n = 1,330$ ). For more details on the Cogstate Test Battery, see  
154 Supplementary Methods 1.1.

### 155 2.2.2 Clinical Assessments

156 *Anxiety and Depressive Disorders (baseline and first follow-up in-person assessments).* The  
157 Mini International Neuropsychiatric Interview – Simplified (MINI) is a reliable, valid, and brief  
158 structured interview that was designed to screen for psychiatric disorders (71-73). Lifelines used  
159 an adapted version of a Dutch translation of the MINI that was administered by trained  
160 interviewers at baseline and self-administered on location at follow-up – details on the version  
161 used in Lifelines have previously been published (74). Participants were considered to meet

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

162 criteria for any depressive disorder if they met the Diagnostic and Statistical Manual of Mental  
163 Disorders (DSM)-IV criteria for Major Depressive Disorder (MDD) *or* dysthymia at the time of  
164 the interview. Impairment was assessed in the MINI for dysthymia but not depression and  
165 consequently, impairment was not used as a criterion for MDD. Any anxiety disorder refers to  
166 meeting current criteria for any one of the following conditions that was assessed using the  
167 MINI: panic disorder, agoraphobia, social phobia, or Generalized Anxiety Disorder (GAD). We  
168 used four diagnostic groups as outcome variables: MDD, any depressive disorder, GAD, and any  
169 anxiety disorder.

170 *Positive and Negative Affect Schedule (baseline in-person assessment).* The Positive and  
171 Negative Affect Schedule (PANAS) is composed of two subscales which are designed to assess  
172 positive and negative affect (75). Each subscale has 10 items (examples of items include  
173 ‘excited’ on positive subscale; ‘upset’ on negative subscale). Participants are asked to rate the  
174 extent that they experienced each item during the last four weeks on a five-point scale (ranging  
175 from ‘not at all’ to ‘extremely’). The outcome is the summed score on each subscale, which  
176 ranges from 10 to 50 (higher value reflects higher positive or negative affect, respectively). The  
177 PANAS has been shown to be reliable and valid (76).

### 178 *2.2.3 C-reactive Protein (baseline in-person assessment)*

179 Participants gave blood samples before 10AM via venipuncture following an overnight fast.  
180 Complete details on blood specimen data collection have previously been reported (64, 70). Due  
181 to assay costs, CRP was assessed in approximately 35% of Lifelines participants and data were  
182 available for 55,098 individuals in the analytic sample. CRP was quantified using three separate  
183 methods over the course of baseline assessment (Method 1: 12.90% of total CRP values assessed  
184 in serum; CardioPhase hsCRP; Method 2: 84.58% of total CRP values, assessed in plasma;

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

185 CardioPhase high sensitivity (hs)CRP, Siemens Healthcare Diagnostics, Marburg, Germany;  
186 Method 3: 2.52% of total CRP values; assessed in plasma; CRPL3, Roche Diagnostics,  
187 Mannheim, Germany). Assay methods 2 and 3 were identical and only differed in terms of the  
188 manufacturer. A conversion formula ( $\text{new} = 0.92 \times \text{old} - 0.01$ ) was derived from an internal  
189 validation using 39 samples, according to the AMC (alternative method comparison, Deming  
190 Regression) protocol in order that Method 1 could be compared with Method 2 and 3 (70). For  
191 CardioPhase hsCRP, the intra-assay coefficient of variability was 3.45% and the inter-assay  
192 coefficient of variability was 3.15%. For CRPL3, the intra-assay coefficient of variability was  
193 4.15% and the inter-assay coefficient of variability was 5.8%.

### 194 2.2.4 Genetic Data

195 Genotype data were available for a subgroup of participants in Lifelines. Genotyping was  
196 conducted using three chip arrays: (i) Illumina CytoSNP-12 Bead Chip v2 array (N=17,033), (ii)  
197 Infinium Global Screening Array (GSA) Beadchip-24 v1.0 (N=38,030), (iii) FinnGen Thermo  
198 Fisher Axiom® custom array (Affymetrix; N=29,166). For details on quality checks (QC's) and  
199 imputation conducted by Lifelines, see Supplementary Methods 1.2. Following Lifelines QC's,  
200 the total sample size for participants who met criteria for this study: CytoSNP (N=14,942), GSA  
201 (N=31,810) and Affymetrix (N=26,334). We applied additional QC's which included removing:  
202 (i) one of the duplicates (individuals who were genotyped on more than one chip) and first-  
203 degree relatives between chips, (ii) non-European individuals (identified by Lifelines), and (iii)  
204 genetic outliers (identified by Lifelines); see Supplementary Figure 1 for more details. This  
205 resulted in a total of 58,713 participants with genetics data included in this study (CytoSNP  
206 N=7,632; GSA N=24,975; Affymetrix N=26,106). For more details on the genetic data in  
207 Lifelines, see Supplementary Methods 1.2.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

### 208 2.2.5 Covariates

209 Covariates included age, sex, educational attainment, body mass index (BMI) and health  
210 status. Age, sex, and educational attainment were self-reported by participants. Educational  
211 attainment was determined using a single-item question and was categorized by Lifelines as: low  
212 [no education, primary education, lower/preparatory vocational education, lower general  
213 secondary education (leaving secondary school aged >16 years)], moderate (intermediate  
214 vocational education/apprenticeship, higher secondary education), and high (higher vocational  
215 education, university). We recoded educational attainment so that higher values represent lower  
216 educational attainment. To estimate body mass index (BMI), height was measured to the closest  
217 0.1 cm and body weight was measured without shoes to 0.1 kg precision. For health status, a  
218 composite measure was created counting several self-reported chronic medical conditions related  
219 to increased levels of inflammation (i.e., arthritis, asthma, coeliac disease, Crohn's disease,  
220 diabetes, and psoriasis); we then categorized participants into those with no relevant chronic  
221 medical condition, 1, 2 or 3+ conditions.

### 222 2.3 Analyses

223 Analyses were conducted in R version 4.1.1.(77)

#### 224 2.3.1 Non-genetic Analyses

225 Multivariable linear and logistic regression models were estimated using base functions in R  
226 (i.e., 'lm', 'glm'). CRP was transformed by natural log to impose a normal distribution.

#### 227 2.3.2 Genetic Risk Scores

228 Genetic risk scores (GRS) were calculated to determine whether GRS for inflammatory  
229 markers (CRP, IL-6, IL-6R, sIL-6R, GlycA) were associated with depression/anxiety, affect and

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

230 cognitive outcomes. To create GRS for each inflammatory marker, we identified genetic variants  
231 (single nucleotide polymorphisms [SNPs]) associated with these proteins in large available  
232 GWAS or using SNP lists from previous publications, see Table 1. For details on the GWAS  
233 used and accessing summary statistics, please see Supplementary Methods 1.3 and  
234 Supplementary Tables 1-2. The following criteria were used to identify SNPs from GWAS for  
235 each inflammatory marker: (i)  $p$ -value  $< 5 \times 10^{-8}$ , (ii) linkage disequilibrium clumping ( $r^2=0.01$ ,  
236 kb=1000 based on the European-clustering individuals in the 1000 genomes reference panel)  
237 using *ld\_clump()* (78) in the *ieugwasr* package, (iii) minor allele frequency  $> 0.01$ . In the primary  
238 analysis, we restricted the SNP set to *cis* variants (SNPs +/- 1Mb from protein coding gene based  
239 on Genome Reference Consortium Human Build used in the GWAS) (79-84). The reason for  
240 restricting to *cis* variants in the primary analysis is because, due to their proximity to the protein  
241 coding gene, they are more likely to be valid instruments, as they are more likely to influence  
242 mRNA expression and protein levels (thus being less pleiotropic) (85). For GlycA, which does  
243 not have a single coding gene due to its composite nature, we used the largest available GWAS  
244 in our primary analysis. In our secondary analyses, we used both *cis* and *trans* variants from  
245 GWAS (i.e., we did not restrict to *cis* variants). Each SNP list (Table 1) was used to create a  
246 weighted GRS for each Lifelines participant. Specifically, the risk alleles were weighted by the  
247 effect size (beta) reported in the GWAS/previous study and then summed to provide a risk score.  
248 Any SNP identified in GWAS/previous study that was not available in Lifelines was replaced  
249 with a proxy (where possible) that had  $r^2 > 0.8$  (using *LDproxy\_batch* function in EUR  
250 population in R), rsID (SNP name) available, SNP available in full summary statistic GWAS,  
251 and in Lifelines (86, 87). GRS were created in Plink v1.90 (88) and continuous phenotypes were  
252 standardized within each chip (z-scored) for direct comparison (CRP levels were log transformed

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

253 but not standardized).

254 To adjust for relatedness within each chip, two approaches were taken. The primary approach

255 applied the GRAMMAR method (89) and the secondary approach involved re-running analyses

256 removing close relatives (up to first-degree, up to second-degree, and up to third-degree), see

257 Supplementary Materials 1.4 and 1.5 for details on how we identified close relatives. We then

258 ran regression models predicting each outcome using the standardized GRS, including top 10

259 genetic PCs (calculated on merged Lifelines genotype data), age, sex, and chip. Maximum

260 sample size for analyses: no relatives within chips removed (N=58,713), up to first-degree

261 removed (N=50,955), up to second-degree removed (N=50,255), up to third-degree removed

262 (N=48,880). Unadjusted analyses are also reported in the Supplementary Tables 5 and 6 for

263 comparison.

### 264 2.3.3 Mendelian randomization

265 To conduct MR using individual level data and two-stage least squares regression, genetic

266 data, exposure data, and outcome data are required. As only CRP is available within the Lifelines

267 cohort (IL-6 and GlycA are not currently available), only this inflammatory marker could be

268 assessed in the MR analysis. Where there was evidence of associations between CRP GRS and

269 outcomes, we followed this up with MR to assess potential causality. Three key assumptions are

270 necessary for valid inferences from MR: (i) genetic variants are robustly associated with the

271 exposure, (ii) genetic variants are not associated with potential confounders, (iii) genetic variants

272 are associated with the outcome only via the exposure. Two-stage least squares regressions were

273 conducted using the *AER* package (90). Analyses were GRAMMAR adjusted for relatedness and

274 all regression models adjusted for age, sex, and chip. To check MR assumptions, we ran linear

275 regressions to test whether CRP GRS were associated with circulating CRP levels in participants

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

276 with both genetic and CRP data available ( $n = 23,607$ ) using the GRAMMAR method. We also  
277 checked whether any inflammatory marker GRS (CRP, IL-6, IL-6R, sIL-6R, GlycA) were  
278 associated with potential confounders (BMI, current smoking status, educational attainment; all  
279 models were adjusted for age, sex, and chip).

280



RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

281 **3. Results**

282 The characteristics of the Lifelines cohort sample are described in Table 2 and Pearson  
283 correlations between study variables are presented in Table 3.

284 **3.1 Association of CRP with affect, depressive and anxiety disorders, and cognitive task**  
285 **performance**

286 The association of (log-transformed) CRP with: (i) clinical outcomes (i.e., MDD, any  
287 depressive disorder, GAD, any anxiety disorder), (ii) positive and negative affect, and (iii) five  
288 cognitive measures [RFFT (executive functioning), detection task (psychomotor speed),  
289 identification task (attention), one-back task (working memory), and one card learning task  
290 (episodic memory)] are illustrated in Table 4, both unadjusted and adjusted for covariates.  
291 Notably, CRP was associated with a greater likelihood of meeting criteria for a range of clinical  
292 outcomes, with a numerically greater likelihood consistently reported for depression as compared  
293 to anxiety at baseline and first follow-up assessment. However, these associations were  
294 attenuated after controlling for confounding by age, sex, education, health status, and BMI.  
295 Higher CRP was also associated with higher negative affect, lower positive affect, and worse  
296 cognitive task performance, although the magnitude of associations was generally very small and  
297 negligible after controlling for covariates.

298 **3.2 Associations of GRSs for inflammatory markers with affect, depressive and anxiety**  
299 **disorders**

300 In the primary analysis, CRP<sub>GRS</sub> (*cis*) was associated with a higher negative affect score  
301 (beta: 0.006; 95% CI: 0.0005 to 0.012,  $p=0.035$ ,  $N=57,946$ ) and increased risk of any anxiety  
302 disorder (beta: 0.002, 95% CI: 0.0001 to 0.004,  $p=0.037$ ,  $N=57,047$ ). GlycA<sub>GRS</sub> was associated

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

303 with higher negative affect score (beta: 0.006, 95% CI: 0.00002 to 0.012,  $p=0.049$ ;  $N=57,946$ )  
304 and increased risk of MDD (beta: 0.001, 95% CI: 0.0001 to 0.002;  $p=0.036$ ;  $N=57,047$ ). Other  
305 inflammatory marker GRSs were not associated with depressive/anxiety disorders or affect  
306 scores ( $ps \geq 0.15$ ). In the secondary analysis, there was evidence that  $CRP_{GRS}$  (*genome-wide*)  
307 was associated with increased risk of any anxiety disorders (beta: 0.002, 95% CI: 0.0003 to  
308 0.004,  $p=0.023$ ,  $N=57,047$ ). There was little evidence that other inflammatory marker GRSs  
309 were associated with depressive/anxiety disorders or affect ( $ps \geq 0.16$ ). For all results, see Figure  
310 1 and Supplementary Table 4. All sensitivity analyses removing differing degrees of related  
311 individuals (up to 1<sup>st</sup>-degree, up to 2<sup>nd</sup>-degree, up to 3<sup>rd</sup>-degree) within chips (non-GRAMMAR  
312 method) did not substantially alter results, see Supplementary Tables 7-12. Although, there was  
313 slightly stronger evidence for associations between  $GlycA_{GRS}$  and negative affect score ( $ps \leq$   
314 0.015) and between  $CRP_{GRS}$  (*cis*) and negative affect score ( $ps \leq 0.033$ ).

### 315 **3.3 Association of GRS for inflammatory markers and cognitive task performance**

316 In primary analyses, inflammatory marker GRSs were not associated with performance on  
317 cognitive tasks ( $ps \geq 0.14$ ), except for  $sIL-6R_{GRS}$  which was negatively associated with episodic  
318 memory performance (one card learning task accuracy; beta: -0.009, 95% CI: -0.017 to -0.002,  
319  $p=0.018$ ,  $N=36,783$ ), see Figure 2 and Supplementary Table 4. In secondary analyses,  
320 inflammatory markers GRSs (*genome-wide*) were not associated with performance on cognitive  
321 tasks ( $ps \geq 0.22$ ). For all results, see Figure 2 and Supplementary Table 4. Sensitivity analyses  
322 after removing related individuals within chips (non-GRAMMAR method) did not alter the  
323 results, see Supplementary Tables 10-12.

### 324 **3.4 Testing potential causality between CRP, negative affect, and anxiety disorders**

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

325 **using Mendelian randomization with individual level data**

326 CRP genetic instruments had F-statistics  $> 10$  (158 for *cis* GRS, 1045 for *genome-wide*  
327 GRS), indicating adequate instrument strength (91). For tests on the MR assumptions, see  
328 Supplementary Results 2.2. There was weak evidence that genetically-proxied CRP (*cis*)  
329 causally increased the risk of any anxiety disorders (beta: 0.12,  $p=0.054$ ,  $N=22,154$ ), and little  
330 evidence on negative affect (beta: 0.27,  $p=0.16$ ;  $N=23,268$ ). Sensitivity analysis removing  
331 related individuals did not alter overall conclusions.

332 The overall pattern of results for the non-genetic and genetic analyses are visualized in  
333 Figure 3.

334

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

335

#### 4. Discussion

336 We conducted complementary non-genetic and genetic analyses to interrogate the  
337 relationship between inflammatory markers and affect, depressive and anxiety disorders, and  
338 cognitive task performance using data from the Lifelines cohort. In non-genetic analyses, higher  
339 CRP was associated with diagnosis of any depressive disorder, positive and negative affect  
340 scores, figural fluency, attention, and psychomotor speed after adjusting for potential  
341 confounders, although the magnitude of these associations was generally small. In genetic  
342 analyses, genetic risk scores for CRP ( $CRP_{GRS}$ ) and GlycA $_{GRS}$  were both associated with higher  
343 negative affect score.  $CRP_{GRS}$  was associated with any anxiety disorder whereas GlycA $_{GRS}$  was  
344 associated with major depressive disorder. Inflammatory marker GRSs were not associated with  
345 cognitive task performance, except for soluble IL-6 $_{GRS}$  which was associated with poorer  
346 memory performance. Individual level MR provided weak evidence for a causal effect of CRP  
347 on any anxiety disorder. Genetic and non-genetic analyses provided consistent evidence for an  
348 association, albeit small, of CRP on negative affect. Genetic analyses suggest that IL-6 signaling  
349 could be relevant for memory, and that the association between CRP and anxiety disorders could  
350 be potentially causal.

#### 351 4.1 Affect

352 Prior studies have generally found inflammation to be associated with higher levels of  
353 negative affect and lower levels of positive affect, although findings are primarily based on  
354 medical populations (92-94) and small community samples (15, 95, 96). To our knowledge, this  
355 is the first large, population-based study to find small but consistent associations of higher CRP  
356 with higher negative affect and lower positive affect, both unadjusted and adjusted for age, sex,  
357 education, health status and BMI. Interestingly, both CRP and GlycA genetic risk scores were

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

358 associated with higher levels of negative affect, but not positive affect. This consistent  
359 association across non-genetic and genetic analyses may reflect the effect of inflammation on a  
360 range of emotional states beyond the cardinal features of depression (i.e., sadness/anhedonia),  
361 which aligns with prior research linking inflammation with fear and irritability (63, 97). Prior  
362 work has shown that inflammation is differentially associated with a specific clinical  
363 presentation characterized by anhedonia and somatic/neurovegetative symptoms (e.g., fatigue,  
364 altered sleep and appetite changes) and further work is needed that more accurately characterize  
365 an inflammatory phenotype in depression (98, 99).

### 366 **4.2 Depression**

367 These data add to a growing body of evidence evaluating the role of inflammation as  
368 measured by circulating CRP levels in the etiology of depression. The results of non-genetic  
369 analyses broadly aligns with results from the UK Biobank cohort in terms of (i) prevalence  
370 estimates of depression and anxiety, (ii) robust univariate associations between CRP and  
371 depression and anxiety, which were generally no longer statistically significant when controlling  
372 for covariates, and (iii) stronger univariate associations for CRP and depression when compared  
373 to anxiety (45). It has long been noted that variables being conceptualized as confounds that  
374 require statistical adjustment (e.g., BMI, medical illness) may, in fact, be key mechanisms in the  
375 pathophysiology of inflammatory depression (100, 101). As such, attenuation of associations  
376 following adjustment for covariates would not, by itself, indicate a non-causal relationship.  
377 Indeed, inflammation may increase risk for depression via increasing the risk of inflammation-  
378 related physical multimorbidity (e.g., cardiovascular disease) (42) – a hypothesis that requires  
379 further investigation.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

380 In genetic analyses, there was also little evidence of an association between CRP<sub>GRS</sub> and  
381 depression outcomes, although there was evidence suggesting GlycA<sub>GRS</sub> increases liability to  
382 MDD. The null CRP findings are consistent with previous MR studies showing no evidence of  
383 effect in MDD (54, 55, 102). However, the MR literature of CRP on depression is mixed with  
384 some studies reporting CRP to decrease (45) or increase (42) risk for depression. It is unclear  
385 what accounts for these mixed findings, but potential factors may include CRP SNP selection,  
386 definition and/or measurement of depression, statistical power, and selection bias (see  
387 Supplementary Discussion). In contrast, MR studies have shown more consistent findings for the  
388 potential causal role of IL-6 on depression (43-45, 103). This is similar to MR findings for  
389 coronary heart disease, where IL-6 but not CRP have been shown to play a potential causal role  
390 (104, 105). Consequently, studies on a broader range of immune markers (e.g. cytokines,  
391 immune cells) and specific immune pathways would be more useful to understand the role of  
392 inflammation in depression, rather than CRP which is a non-specific marker of systemic immune  
393 activation (106).

### 394 **4.3 Cognitive Task Performance**

395 We observed relatively small effects of CRP on cognitive task performance, and in genetic  
396 analysis only sIL-6R<sub>GRS</sub> was associated with poor memory performance out of all inflammatory  
397 markers and cognitive tasks examined. Our findings contribute to inconsistent findings across  
398 population-based cohorts assessing circulating inflammatory biomarkers and cognitive  
399 performance where associations observed in population-based studies (22, 30, 107) often are not  
400 large in magnitude or consistently observed (56). Few MR studies have been conducted on the  
401 role of inflammation on cognition. Consistent with results presented here, our previous MR study  
402 examining the role of the same inflammatory markers (i.e., CRP, IL-6, IL-6R, sIL-6R, GlycA)

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

403 on specific executive functions within the ALSPAC cohort (e.g., emotion recognition, working  
404 memory, response inhibition (56)) found little evidence of a potential causal effect. However,  
405 Pagoni et al. recently reported that other cytokines and chemokines (i.e., Eotaxin , IL-8, MCP1)  
406 may be causally related to lower fluid intelligence (and IL-4 with higher fluid intelligence) (57).  
407 The finding regarding sIL-6R and memory performance is novel and would align with  
408 convergent evidence that trans-signaling – in which sIL-6R plays a critical role – may be  
409 responsible for the deleterious effect of IL-6 on cognitive functioning (47, 108).

410 Interpreting the relationship between inflammation and cognitive task performance in  
411 population-based studies is difficult for several reasons. First, there is considerable heterogeneity  
412 in the type and breadth of cognitive abilities assessed across studies and there is a need for future  
413 studies to more uniformly include well-validated measures assessing individual differences  
414 [rather than detecting pathological states (e.g., dementia, epilepsy)] that characterize a broad  
415 range of cognitive functions (109). There is a similar need to measure and conceptualize the  
416 impact that inflammation has on other psychological functions that impact cognition (e.g.,  
417 reward process, aversive process) – there is strong theoretical work and empirical data to support  
418 an indirect effect of inflammation on cognition via, for instance, dysregulated reward circuitry  
419 that impact performance on cognitive tasks via decreased motivation or increased fatigue (110).  
420 Moreover, there are a range of sociodemographic factors that may moderate the association  
421 between inflammation and cognition – prior work has found that inflammation and cognition  
422 may differ based on age and sex (111, 112). It is reasonable to assume, for instance, that modest  
423 increases in inflammation may exert a cumulative effect across the lifespan, and thus may only  
424 be detected later in life and/or in specific domains of cognition.

### 425 **4.4 Anxiety**

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

426 In the non-genetic analyses, circulating CRP levels was associated with a modestly increased  
427 likelihood of meeting criteria for anxiety disorders, although this association was substantially  
428 attenuated following adjustments for covariates. Prior research in population-based cohorts have  
429 found CRP to associated with an increased risk for anxiety disorders (113, 114), although results  
430 are inconsistent and other studies indicate that anxiety prospectively predicts an increase in  
431 circulating CRP levels (115). The MR analysis suggests a potential causal role of CRP on any  
432 anxiety disorder (which covers a broad range of anxiety-related conditions including panic  
433 disorder, social phobia, agoraphobia, GAD). Prior theory has primarily focused on anxiety as a  
434 cause of inflammation [see O'Donovan et al. for an excellent review (116)]; however, alternative  
435 theories suggest that inflammatory physiology is implicated in both sickness behaviors (e.g.,  
436 anhedonia, social withdrawal) *and* anxiety arousal and alarm (117), which would align with the  
437 results presented here.

### 438 **4.5 Limitations**

439 In this study we used a large and broadly representative population-based sample, and we  
440 employed a triangulation of methods (non-genetic and genetic analyses) which increases  
441 confidence in the inferences drawn. Nevertheless, results should be considered in the context of  
442 the limitations of the study. First, although broadly representative, like other cohort studies (e.g.,  
443 UK Biobank), the Lifelines cohort predominantly includes individuals of European descent and  
444 is less representative of individuals from low socioeconomic status (118), which consequentially  
445 limits the generalizability of findings. Second, analyses were not corrected for multiple  
446 comparisons. To check effects are not due to Type 1 errors, there is a need to replicate these  
447 findings in other cohorts. Moreover, as effect sizes reported are small and reflect associations in  
448 the general population, there is a need for studies to investigate whether there are sub-groups for



## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

449 whom these associations may be larger (e.g., older age, clinical populations). Third, in the  
450 genetic analysis the CRP GRS explained 1-4% of the variance in CRP [a level of variance  
451 consistent with similar analyses in the ALSPAC cohort (56)] and few cases of depression were  
452 observed in Lifelines [although the point prevalence of approximately 4% is consistent with  
453 reported population point prevalence estimates (119)]. It is possible that this limited our capacity  
454 to detect potential causal effects, were they small in magnitude or non-linear. Fourth, the  
455 CogState tasks used in the current study may not be optimal for detecting individual differences  
456 in healthy individuals, or even in some conditions such as depression; multiple studies have  
457 shown that the CogState tasks used in this study do not improve in successful antidepressant  
458 trials, even when improvement in other cognitive measures are observed (120-122). Fifth,  
459 although we include multiple instruments related to IL-6 (i.e., genetic variants related to IL-6 and  
460 sIL-6R levels), most instruments contain few genetic variants ( $\leq 3$  SNPs) and genetic variants for  
461 IL-6 and sIL-6R overlap. While sIL-6R is involved in IL-6 trans-signaling, the overlap of SNPs  
462 makes it challenging to interpret the effect of these genetic variants on different immune  
463 phenotypes specifically (i.e., IL-6 levels vs IL-6 signaling). Future studies are needed to (1)  
464 better understand the biological role of these genetic variants and (2) develop instruments  
465 proxying specific IL-6 signaling pathways including IL-6 trans-signaling. Finally, it is worth  
466 considering that some instruments in the genetic analyses were associated with potential  
467 confounds, although it is unlikely that the small effects observed for some confounds  
468 substantially bias parameter estimates.

### 469 **4.6 Conclusions**

470 Genetic and non-genetic analyses provide consistent evidence for a modest effect of CRP on  
471 negative affect. Genetic analyses suggest that IL-6 signaling could be relevant for memory, and

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

472 that the association between CRP and anxiety disorders could be causal. Overall, these results  
473 suggest that inflammation may affect a range of emotional states beyond the cardinal features of  
474 depression. However, given the small effect sizes and multiple tests conducted, future studies are  
475 required to investigate whether effects are moderated by sub-groups and whether these findings  
476 replicate in other cohorts.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489

**Funding**

This work was supported by Harvard University’s Mind Brain Behavior Interfaculty Initiative and National Institute of Mental Health grant K23MH132893 (Dr. Mac Giollabhui), and a UK Medical Research Council (MRC) grant to GMK (MC\_UU\_00032/06) which forms part of the Integrative Epidemiology Unit (IEU) at the University of Bristol. The MRC grant also supports CS and EMF. GMK acknowledges additional funding support from the Wellcome Trust (201486/Z/16/Z and 201486/B/16/Z), MRC (MR/W014416/1; MR/S037675/1; and MR/Z50354X/1), and the UK National Institute of Health and Care Research (NIHR) Bristol Biomedical Research Centre (NIHR 203315). GH and GDS are supported by the MRC (MC\_UU\_00032/01), and the NIHR Bristol Biomedical Research Centre (NIHR 203315). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care, UK.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

490

**Acknowledgments**

491       The Lifelines initiative has been made possible by subsidy from the Dutch Ministry of  
492 Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical  
493 Center Groningen (UMCG), Groningen University and the Provinces in the North of the  
494 Netherlands (Drenthe, Friesland, Groningen). The generation and management of GWAS  
495 genotype data for the Lifelines Cohort Study is supported by the UMCG Genetics Lifelines  
496 Initiative (UGLI). UGLI is partly supported by a Spinoza Grant from NWO, awarded to Cisca  
497 Wijmenga. The authors wish to acknowledge the services of the Lifelines Cohort Study, the  
498 contributing research centers delivering data to Lifelines, and all the study participants.

499

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

500

**Conflict of Interest**

501

No conflicts of interest were reported.

502

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY  
DISORDERS AND COGNITIVE TASK PERFORMANCE

503

**Author Contributions**

504 NMG, GMK, CH and CS conceptualized and designed the study. NMG conducted the non-  
505 genetic analysis. CS conducted the genetic analyses. NMG and CS wrote the first draft of the  
506 paper. All authors advised on the project/analysis and critically reviewed the final version of the  
507 manuscript. CH and GMK provided overall supervision for this project.

508

509

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

510

### References

- 511 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. (2020): Global burden of 369  
512 diseases and injuries in 204 countries and territories, 1990&#x2013;2019: a systematic analysis for the  
513 Global Burden of Disease Study 2019. *The Lancet*. 396:1204-1222.
- 514 2. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, et al. (2013): The  
515 epidemiological modelling of major depressive disorder: application for the Global Burden of Disease  
516 Study 2010. *PLoS One*. 8:e69637.
- 517 3. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. (2018): Global, regional, and  
518 national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195  
519 countries and territories, 1990&#x2013;2017: a systematic analysis for the Global Burden of Disease  
520 Study 2017. *The Lancet*. 392:1789-1858.
- 521 4. Taylor CA, Boudin ED, McGuire LC (2018): Subjective Cognitive Decline Among Adults Aged ≥45  
522 Years - United States, 2015-2016. *MMWR Morb Mortal Wkly Rep*. 67:753-757.
- 523 5. Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014): Prevalence, mechanisms, and  
524 management of cancer-related cognitive impairment. *Int Rev Psychiatry*. 26:102-113.
- 525 6. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. (2022): Fatigue and cognitive  
526 impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun*.  
527 101:93-135.
- 528 7. Wang Y, Liu M, Lu Q, Farrell M, Lappin JM, Shi J, et al. (2020): Global prevalence and burden of  
529 HIV-associated neurocognitive disorder. *A meta-analysis*. 95:e2610-e2621.
- 530 8. Barreira DP, Marinho RT, Bicho M, Fialho R, Ouakinin SRS (2018): Psychosocial and  
531 Neurocognitive Factors Associated With Hepatitis C - Implications for Future Health and Wellbeing. *Front*  
532 *Psychol*. 9:2666.
- 533 9. Fava M, Mahableshwarkar AR, Jacobson W, Zhong W, Keefe RS, Olsen CK, et al. (2018): What is  
534 the overlap between subjective and objective cognitive impairments in MDD? *Ann Clin Psychiatry*.  
535 30:176-184.
- 536 10. Keefe RS, Harvey PD (2012): Cognitive impairment in schizophrenia. *Novel antischizophrenia*  
537 *treatments*.11-37.
- 538 11. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006): Evaluation of  
539 outcomes with citalopram for depression using measurement-based care in STAR\* D: implications for  
540 clinical practice. *Am J Psychiatry*. 163:28-40.
- 541 12. Ritchie K, Chan D (2021): The emergence of cognitive COVID. *World Psychiatry*. 20:52-53.
- 542 13. Fesharaki-Zadeh A, Lowe N, Arnsten AFT (2023): Clinical experience with the  $\alpha$ 2A-adrenoceptor  
543 agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”.  
544 *Neuroimmunology Reports*. 3:100154.
- 545 14. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. (2010): A meta-analysis of  
546 cytokines in major depression. *Biol Psychiatry*. 67:446-457.
- 547 15. Ironson G, Banerjee N, Fitch C, Krause N (2018): Positive emotional well-being, health Behaviors,  
548 and inflammation measured by C-Reactive protein. *Soc Sci Med*. 197:235-243.
- 549 16. Felger JC, Treadway MT (2017): Inflammation Effects on Motivation and Motor Activity: Role of  
550 Dopamine. *Neuropsychopharmacology*. 42:216-241.
- 551 17. Mac Giollabhui N, Ng TH, Ellman LM, Alloy LB (2021): The longitudinal associations of  
552 inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-  
553 regression. *Mol Psychiatry*. 26:3302-3314.
- 554 18. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB (2014): Association of serum  
555 interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a  
556 population-based longitudinal study. *JAMA Psychiatry*. 71:1121-1128.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 557 19. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA (2010): Association of C-  
558 reactive protein with cognitive impairment. *Arch Neurol.* 67:87-92.
- 559 20. Baune B, Ponath G, Golledge J, Varga G (2008): Association between IL-8 cytokine and cognitive  
560 performance in an elderly general population—the MEMO-Study. *Neurobiol Aging.* 29:937-944.
- 561 21. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. (2001): Cytokine-  
562 associated emotional and cognitive disturbances in humans. *Arch Gen Psychiatry.* 58:445-452.
- 563 22. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, et al. (2014): Interleukin-  
564 6 and C-reactive protein as predictors of cognitive decline in late midlife. *Neurology.* 83:486-493.
- 565 23. Crisan AF, Oancea C, Timar B, Fira-Mladinescu O, Crisan A, Tudorache V (2014): Cognitive  
566 impairment in chronic obstructive pulmonary disease. *PLoS One.* 9:e102468.
- 567 24. Huang YS, Guilleminault C, Hwang FM, Cheng C, Lin CH, Li HY, et al. (2016): Inflammatory  
568 cytokines in pediatric obstructive sleep apnea. *Medicine.* 95:e4944.
- 569 25. Li X, Robertson CM, Yu X, Cheyesh A, Dinu IA, Li J (2014): Early postoperative systemic  
570 inflammatory response is an important determinant for adverse 2-year neurodevelopment-associated  
571 outcomes after the Norwood procedure. *J Thorac Cardiovasc Surg.* 148:202-206.
- 572 26. Nightingale S, Dreyer AJ, Saylor D, Gisslén M, Winston A, Joska JA (2021): Moving on From  
573 HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human  
574 Immunodeficiency Virus and a Proposed Way Forward. *Clin Infect Dis.* 73:1113-1118.
- 575 27. Mac Giollabhui N (2021): Inflammation and depression: Research designs to better understand  
576 the mechanistic relationships between depression, inflammation, cognitive dysfunction, and their  
577 shared risk factors. *Brain Behav Immun Health.* 15:100278.
- 578 28. Krogh J, Benros ME, Jorgensen MB, Vesterager L, Elfving B, Nordentoft M (2014): The  
579 association between depressive symptoms, cognitive function, and inflammation in major depression.  
580 *Brain Behav Immun.* 35:70-76.
- 581 29. Goldsmith DR, Haroon E, Woolwine BJ, Jung MY, Wommack EC, Harvey PD, et al. (2016):  
582 Inflammatory markers are associated with decreased psychomotor speed in patients with major  
583 depressive disorder. *Brain Behav Immun.* 56:281-288.
- 584 30. Mac Giollabhui N, Alloy LB, Hartman CA (2021): Investigating whether depressed youth  
585 exhibiting elevated C reactive protein perform worse on measures of executive functioning, verbal  
586 fluency and episodic memory in a large, population based sample of Dutch adolescents. *Brain Behav*  
587 *Immun.* 94:369-380.
- 588 31. Ribeiro-Santos R, Lucio Teixeira A, Vinicius Salgado J (2014): Evidence for an immune role on  
589 cognition in schizophrenia: a systematic review. *Curr Neuropharmacol.* 12:273-280.
- 590 32. Mac Giollabhui N, Swistun D, Murray S, Moriarity DP, Kautz MM, Ellman LM, et al. (2020):  
591 Executive dysfunction in depression in adolescence: the role of inflammation and higher body mass.  
592 *Psychol Med.* 50:683-691.
- 593 33. McAfoose J, Baune BT (2009): Evidence for a cytokine model of cognitive function. *Neurosci*  
594 *Biobehav Rev.* 33:355-366.
- 595 34. Carvalho AF, Miskowiak KK, Hyphantis TN, Kohler CA, Alves GS, Bortolato B, et al. (2014):  
596 Cognitive dysfunction in depression - pathophysiology and novel targets. *CNS Neurol Disord Drug*  
597 *Targets.* 13:1819-1835.
- 598 35. Chesnokova V, Pechnick RN, Wawrowsky K (2016): Chronic peripheral inflammation,  
599 hippocampal neurogenesis, and behavior. *Brain Behav Immun.* 58:1-8.
- 600 36. Goldsmith D, Bekhbat M, Mehta ND, Felger JC (2023): Inflammation-related functional and  
601 structural dysconnectivity as a pathway to psychopathology. *Biol Psychiatry.* 93:405-418.
- 602 37. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR (2010):  
603 Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. *Biol*  
604 *Psychiatry.* 68:748-754.



## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 605 38. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD (2008): Peripheral Inflammation is  
606 Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans. *Biol Psychiatry*.  
607 63:1022-1029.
- 608 39. Harrison NA, Cercignani M, Voon V, Critchley HD (2015): Effects of inflammation on  
609 hippocampus and substantia nigra responses to novelty in healthy human participants.  
610 *Neuropsychopharmacology*. 40:831-838.
- 611 40. Davey Smith G, Ebrahim S (2003): 'Mendelian randomization': can genetic epidemiology  
612 contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 32:1-22.
- 613 41. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al. (2022):  
614 Mendelian randomization. *Nat Rev Methods Primers*. 2:6.
- 615 42. Khandaker GM, Zuber V, Rees JMB, Carvalho L, Mason AM, Foley CN, et al. (2020): Shared  
616 mechanisms between coronary heart disease and depression: findings from a large UK general  
617 population-based cohort. *Mol Psychiatry*. 25:1477-1486.
- 618 43. Perry BI, Upthegrove R, Kappelmann N, Jones PB, Burgess S, Khandaker GM (2021): Associations  
619 of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-  
620 directional two-sample mendelian randomization study. *Brain Behav Immun*. 97:176-185.
- 621 44. Kelly KM, Smith JA, Mezuk B (2021): Depression and interleukin-6 signaling: A Mendelian  
622 Randomization study. *Brain Behav Immun*. 95:106-114.
- 623 45. Ye Z, Kappelmann N, Moser S, Smith GD, Burgess S, Jones PB, et al. (2021): Role of Inflammation  
624 in Depression and Anxiety: Tests for Disorder Specificity, Linearity and Potential Causality of Association  
625 in the UK Biobank. *medRxiv*.
- 626 46. Hunter CA, Jones SA (2015): IL-6 as a keystone cytokine in health and disease. *Nat Immunol*.  
627 16:448-457.
- 628 47. Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J (2023): Targeting IL-6 trans-signalling:  
629 past, present and future prospects. *Nat Rev Immunol*. 23:666-681.
- 630 48. Crick DC, Khandaker GM, Halligan SL, Burgner D, Mansell T, Fraser A (2023): Comparison of the  
631 stability of glycoprotein acetyls and high sensitivity C-reactive protein as markers of chronic  
632 inflammation. *Immunology*.
- 633 49. Connelly MA, Otvos JD, Shalaurava I, Playford MP, Mehta NN (2017): GlycA, a novel biomarker  
634 of systemic inflammation and cardiovascular disease risk. *J Transl Med*. 15:1-5.
- 635 50. Otvos JD, Shalaurava I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. (2015):  
636 GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. *Clin Chem*.  
637 61:714-723.
- 638 51. Ritchie Scott C, Würtz P, Nath Artika P, Abraham G, Havulinna Aki S, Fearnley Liam G, et al.  
639 (2015): The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of  
640 Severe Infection. *Cell Systems*. 1:293-301.
- 641 52. Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S, et al. (2020): Dissecting  
642 the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A  
643 Genetic Correlation and 2-Sample Mendelian Randomization Study. *JAMA Psychiatry*.
- 644 53. Crick DCP, Sanderson E, Jones H, Goulding N, Borges MC, Clayton G, et al. (2023): Glycoprotein  
645 acetyls and depression: Testing for directionality and potential causality using longitudinal data and  
646 Mendelian randomization analyses. *J Affect Disord*. 335:431-439.
- 647 54. Bekkevold O-J, Damås JK, Brumpton BM, Åsvold BO (2023): The causal role of C-reactive protein  
648 and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation  
649 analyses in the HUNT study. *Psychol Med*. 1-8.
- 650 55. Galan D, Perry BI, Warrier V, Davidson CC, Stupart O, Easton D, et al. (2022): Applying Mendelian  
651 randomization to appraise causality in relationships between smoking, depression and inflammation. *Sci*  
652 *Rep*. 12:15041.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 653 56. Slaney C, Sallis HM, Jones HJ, Dardani C, Tilling K, Munafo MR, et al. (2023): Association between  
654 inflammation and cognition: Triangulation of evidence using a population-based cohort and Mendelian  
655 randomization analyses. *Brain Behav Immun*. 110:30-42.
- 656 57. Pagoni P, Korologou-Linden RS, Howe LD, Davey Smith G, Ben-Shlomo Y, Stergiakouli E, et al.  
657 (2022): Causal effects of circulating cytokine concentrations on risk of Alzheimer's disease and cognitive  
658 function. *Brain Behav Immun*. 104:54-64.
- 659 58. Fleshner M, Frank M, Maier SF (2017): Danger Signals and Inflammasomes: Stress-Evoked Sterile  
660 Inflammation in Mood Disorders. *Neuropsychopharmacology*. 42:36-45.
- 661 59. Slavich GM (2020): Social safety theory: a biologically based evolutionary perspective on life  
662 stress, health, and behavior. *Annu Rev Clin Psychol*. 16.
- 663 60. Murphy K, Weaver C (2017): *Janeway's Immunobiology (9th Edition)*. New York, New York:  
664 Garland Science, Taylor & Francis Group.
- 665 61. Kiecolt-Glaser JK, Derry HM, Fagundes CP (2015): Inflammation: depression fans the flames and  
666 feasts on the heat. *Am J Psychiatry*. 172:1075-1091.
- 667 62. Miller AH, Raison CL (2016): The role of inflammation in depression: from evolutionary  
668 imperative to modern treatment target. *Nat Rev Immunol*. 16:22-34.
- 669 63. Slavich GM, Irwin MR (2014): From stress to inflammation and major depressive disorder: a  
670 social signal transduction theory of depression. *Psychol Bull*. 140:774-815.
- 671 64. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. (2015): Cohort Profile:  
672 Lifelines, a three-generation cohort study and biobank. *Int J Epidemiol*. 44:1172-1180.
- 673 65. Sijtsma A, Rienks J, van der Harst P, Navis G, Rosmalen JGM, Dotinga A (2021): Cohort Profile  
674 Update: Lifelines, a three-generation cohort study and biobank. *Int J Epidemiol*. 51:e295-e302.
- 675 66. Ross TP (2014): The reliability and convergent and divergent validity of the Ruff Figural Fluency  
676 Test in healthy young adults. *Arch Clin Neuropsychol*. 29:806-817.
- 677 67. Ruff RM, Light RH, Evans RW (1987): The Ruff Figural Fluency Test: a normative study with  
678 adults. *Dev Neuropsychol*. 3:37-51.
- 679 68. Kuiper JS, Oude Voshaar RC, Verhoeven FE, Zuidema SU, Smidt N (2017): Comparison of  
680 cognitive functioning as measured by the Ruff Figural Fluency Test and the CogState computerized  
681 battery within the Lifelines Cohort Study. *BMC psychology*. 5:1-12.
- 682 69. Gulpers B, Lugtenburg A, Zuidersma M, Verhey F, Voshaar RO (2018): Anxiety disorders and  
683 figural fluency: A measure of executive function. *J Affect Disord*. 234:38-44.
- 684 70. Mac Giollabhui N, Alloy LB, Schweren LJS, Hartman CA (2021): Investigating whether a  
685 combination of higher CRP and depression is differentially associated with worse executive functioning  
686 in a cohort of 43,896 adults. *Brain Behav Immun*. 96:127-134.
- 687 71. Overbeek T, Schruers K, Griez E (1999): MINI: Mini international neuropsychiatric interview,  
688 Dutch version 5.0. 0 (DSM-IV). *Maastricht: University of Maastricht*.
- 689 72. Hergueta T, Weiller E (2017): *MINI-S for DSM-5, Dutch version*.
- 690 73. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan K, et al. (1997): The Mini  
691 International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and  
692 validity according to the CIDI. *Eur Psychiatry*. 12:224-231.
- 693 74. Wanders RB, van Loo HM, Vermunt JK, Meijer RR, Hartman CA, Schoevers RA, et al. (2016):  
694 Casting wider nets for anxiety and depression: disability-driven cross-diagnostic subtypes in a large  
695 cohort. *Psychol Med*. 46:3371-3382.
- 696 75. Watson D, Clark LA, Tellegen A (1988): Development and validation of brief measures of positive  
697 and negative affect: the PANAS scales. *J Pers Soc Psychol*. 54:1063.
- 698 76. Crawford JR, Henry JD (2004): The Positive and Negative Affect Schedule (PANAS): Construct  
699 validity, measurement properties and normative data in a large non-clinical sample. *Br J Clin Psychol*.  
700 43:245-265.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 701 77. Team RC (2021): R: A language and environment for statistical computing. Vienna, Austria: R  
702 Foundation for Statistical Computing.
- 703 78. Hemani G, Elsworth B, Palmer T, Rasteiro R (2024): ieugwasr: Interface to the 'OpenGWAS'  
704 Database API. R package version 0.2.2-9000. <https://github.com/MRCIEU/ieugwasr>.
- 705 79. Said S, Pazoki R, Karhunen V, Vösa U, Ligthart S, Bodinier B, et al. (2022): Genetic analysis of over  
706 half a million people characterises C-reactive protein loci. *Nat Commun.* 13:2198.
- 707 80. Collaboration IRGCERF, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, et al. (2012):  
708 Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.  
709 *Lancet.* 379:1205-1213.
- 710 81. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, et al. (2012): The  
711 interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation  
712 analysis. *Lancet.* 379:1214-1224.
- 713 82. Rosa M, Chignon A, Li Z, Boulanger MC, Arsenault BJ, Bosse Y, et al. (2019): A Mendelian  
714 randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity.  
715 *NPJ Genom Med.* 4:23.
- 716 83. Project IOG (2023): Glycoprotein acetyls Dataset: met-d-GlycA.
- 717 84. Prins BP, Abbasi A, Wong A, Vaez A, Nolte I, Franceschini N, et al. (2016): Investigating the  
718 Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-  
719 Scale Cross-Consortium Mendelian Randomization Study. *PLoS Med.* 13:e1001976.
- 720 85. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, et al. (2016): Selecting  
721 instruments for Mendelian randomization in the wake of genome-wide association studies. *Int J*  
722 *Epidemiol.* 45:1600-1616.
- 723 86. Machiela MJ, Chanock SJ (2015): LDlink: a web-based application for exploring population-  
724 specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics.*  
725 31:3555-3557.
- 726 87. Myers TA, Chanock SJ, Machiela MJ (2020): LDlinkR: An R Package for Rapidly Calculating Linkage  
727 Disequilibrium Statistics in Diverse Populations. *Frontiers in Genetics.* 11.
- 728 88. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. (2007): PLINK: a tool  
729 set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 81:559-575.
- 730 89. Aulchenko YS, De Koning D-J, Haley C (2007): Genomewide rapid association using mixed model  
731 and regression: a fast and simple method for genomewide pedigree-based quantitative trait loci  
732 association analysis. *Genetics.* 177:577-585.
- 733 90. Kleiber C, Zeileis A (2008): *Applied econometrics with R*. Springer Science & Business Media.
- 734 91. Burgess S, Thompson SG (2011): Avoiding bias from weak instruments in Mendelian  
735 randomization studies. *Int J Epidemiol.* 40:755-764.
- 736 92. Slavish DC, Jones DR, Smyth JM, Engeland CG, Song S, McCormick NM, et al. (2020): Positive and  
737 Negative Affect and Salivary Markers of Inflammation Among Young Adults. *Int J Behav Med.* 27:282-  
738 293.
- 739 93. Brouwers C, Mommersteeg PM, Nyklíček I, Pelle AJ, Westerhuis BL, Szabó BM, et al. (2013):  
740 Positive affect dimensions and their association with inflammatory biomarkers in patients with chronic  
741 heart failure. *Biol Psychol.* 92:220-226.
- 742 94. Sepah SC, Bower JE (2009): Positive affect and inflammation during radiation treatment for  
743 breast and prostate cancer. *Brain Behav Immun.* 23:1068-1072.
- 744 95. Stellar JE, John-Henderson N, Anderson CL, Gordon AM, McNeil GD, Keltner D (2015): Positive  
745 affect and markers of inflammation: discrete positive emotions predict lower levels of inflammatory  
746 cytokines. *Emotion.* 15:129.
- 747 96. Lin C, Michopoulos V, Powers A, Wingo AP, Schwartz A, Bradley B, et al. (2018): Affect,  
748 inflammation, and health in urban at-risk civilians. *J Psychiatr Res.* 104:24-31.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE


- 749 97. Boylan JM, Lewis TT, Coe CL, Ryff CD (2015): Educational Status, Anger, and Inflammation in the  
750 MIDUS National Sample: Does Race Matter? *Ann Behav Med.* 49:570-578.
- 751 98. Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB, et al. (2021): Association of  
752 inflammation with depression and anxiety: evidence for symptom-specificity and potential causality  
753 from UK Biobank and NESDA cohorts. *Mol Psychiatry.* 26:7393-7402.
- 754 99. Milaneschi Y, Lamers F, Berk M, Penninx B (2020): Depression Heterogeneity and Its Biological  
755 Underpinnings: Toward Immunometabolic Depression. *Biol Psychiatry.* 88:369-380.
- 756 100. Felger JC, Haroon E, Miller AH (2018): What's CRP got to do with it? Tackling the complexities of  
757 the relationship between CRP and depression. *Brain Behav Immun.* 73:163-164.
- 758 101. Mac Giollabhui N, Ellman LM, Coe CL, Byrne ML, Abramson LY, Alloy LB (2020): To exclude or not  
759 to exclude: Considerations and recommendations for C-reactive protein values higher than 10 mg/L.  
760 *Brain Behav Immun.* 87:898-900.
- 761 102. Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG (2013): Elevated C-Reactive  
762 Protein Levels, Psychological Distress, and Depression in 73 131 Individuals. *JAMA Psychiatry.* 70:176.
- 763 103. Khandaker GM, Zuber V, Rees JM, Carvalho L, Mason AM, Foley CN, et al. (2019): Shared  
764 mechanisms between coronary heart disease and depression: findings from a large UK general  
765 population-based cohort. *Mol Psychiatry.* 1-10.
- 766 104. Consortium I-RMRA (2012): The interleukin-6 receptor as a target for prevention of coronary  
767 heart disease: a mendelian randomisation analysis. *The Lancet.* 379:1214-1224.
- 768 105. Collaboration CRPCHDG (2011): Association between C reactive protein and coronary heart  
769 disease: mendelian randomisation analysis based on individual participant data. *BMJ.* 342.
- 770 106. Foley ÉM, Slaney C, Donnelly NA, Kaser M, Ziegler L, Khandaker GM (2024): A novel biomarker of  
771 interleukin 6 activity and clinical and cognitive outcomes in depression. *Psychoneuroendocrinology.*  
772 164:107008.
- 773 107. Zainal NH, Newman MG (2022): Depression and worry symptoms predict future executive  
774 functioning impairment via inflammation. *Psychol Med.* 52:3625-3635.
- 775 108. Mac Giollabhui N, Foster S, Lowry CA, Mischoulon D, Raison CL, Nyer M (2022): Interleukin-6  
776 receptor antagonists in immunopsychiatry: Can they lead to increased interleukin-6 in the central  
777 nervous system (CNS) and worsening psychiatric symptoms? *Brain Behav Immun.* 103:202-204.
- 778 109. Boogert NJ, Madden JR, Morand-Ferron J, Thornton A (2018): Measuring and understanding  
779 individual differences in cognition. *Philos Trans R Soc Lond B Biol Sci.* 373.
- 780 110. Mac Giollabhui N, Mischoulon D, Dunlop BW, Kinkead B, Schettler PJ, Liu RT, et al. (2023):  
781 Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3  
782 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary  
783 results from a randomized controlled trial. *Brain Behav Immun Health.* 32:100666.
- 784 111. Klein SL, Flanagan KL (2016): Sex differences in immune responses. *Nat Rev Immunol.* 16:626-  
785 638.
- 786 112. Ferrucci L, Fabbri E (2018): Inflammageing: chronic inflammation in ageing, cardiovascular  
787 disease, and frailty. *Nat Rev Cardiol.* 15:505-522.
- 788 113. Vogelzangs N, Beekman ATF, de Jonge P, Penninx BWJH (2013): Anxiety disorders and  
789 inflammation in a large adult cohort. *Transl Psychiatry.* 3:e249-e249.
- 790 114. Costello H, Gould RL, Abrol E, Howard R (2019): Systematic review and meta-analysis of the  
791 association between peripheral inflammatory cytokines and generalised anxiety disorder. *BMJ open.*  
792 9:e027925.
- 793 115. Glaus J, von Känel R, Lasserre AM, Strippoli MPF, Vandeleur CL, Castelao E, et al. (2018): The  
794 bidirectional relationship between anxiety disorders and circulating levels of inflammatory markers:  
795 results from a large longitudinal population-based study. *Depress Anxiety.* 35:360-371.

## RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE


- 796 116. O'Donovan A, Slavich GM, Epel ES, Neylan TC (2013): Exaggerated neurobiological sensitivity to  
797 threat as a mechanism linking anxiety with increased risk for diseases of aging. *Neurosci Biobehav Rev.*  
798 37:96-108.
- 799 117. Raison CL, Miller AH (2017): Pathogen–host defense in the evolution of depression: insights into  
800 epidemiology, genetics, bioregional differences and female preponderance. *Neuropsychopharmacology.*  
801 42:5-27.
- 802 118. Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N (2015): Representativeness of  
803 the LifeLines Cohort Study. *PLoS One.* 10:e0137203.
- 804 119. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. (2020): Global burden of 369  
805 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global  
806 Burden of Disease Study 2019. *The Lancet.* 396:1204-1222.
- 807 120. Freeman MP, Cheng LJ, Moustafa D, Davies A, Sosinsky AZ, Wang B, et al. (2017): Vortioxetine  
808 for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal  
809 transition. *Ann Clin Psychiatry.* 29:249-257.
- 810 121. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS (2015): A randomized, placebo-  
811 controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive  
812 function in major depressive disorder. *Neuropsychopharmacology.* 40:2025-2037.
- 813 122. Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR (2008): Quetiapine augmentation in  
814 depressed patients with partial response to antidepressants. *Hum Psychopharmacol.* 23:653-660.

815


**Figure 1.** Associations of genetic risk scores for inflammatory markers with mood, anxiety disorders and positive and negative affect scores.



**Figure 2.** Associations of genetic risk scores for inflammatory markers with cognitive task performance.



**Figure 3.** Visualisation of the overall pattern of results for CRP in the cohort and genetic analyses.





**Table 1. Large available genome-wide association studies and previous publications used to identify single nucleotide polymorphisms associated with systemic inflammatory markers.**

<b>Marker</b>	<b>Author of GWAS/ Instrument</b>	<b>Sample size</b>	<b>Outcome</b>	<b>SNPs Identified</b>	<b>SNPs available on each chip</b>
<b>Primary analysis</b>					
CRP	(Said et al., 2022)	575,531	Circulating CRP	19	16
IL-6R	(Ahluwalia et al., 2021)	52,654	Circulating IL-6	2	2
	(Sarwar et al., 2012)	27,185	Circulating IL-6	1	1
sIL6R	(Rosa et al., 2019)	3,301	Circulating sIL6R	34	34
GlycA	(Borges, 2020)	115,078	Circulating GlycA	87	73-74
<b>Secondary analysis</b>					
CRP	(Said et al., 2022)	575,531	Circulating CRP	485	445-446
IL-6	(Ahluwalia et al., 2021)	52,654	Circulating IL-6	3	2-3

CRP = C-reactive protein; IL-6 = interleukin-6, IL-6R = IL-6 receptor, sIL6R = soluble IL-6R

**Table 2. Lifelines Cohort Sample Characteristics at Baseline and First Follow-up Assessment**

<u>Measures</u>	<u>Cohort Analyses</u>	<u>Genetic Analyses</u>
	<u>(n = 147,815)</u>	<u>(n = 58,713)</u>
<b>Baseline Assessment</b>		
Age [Mean ( <i>SD</i> )]	44.52 (13.12) n = 147,815	43.04 (13.56) n = 58,713
Sex (% Female)	59 % n = 147,815	60% n = 58,695
Education (N %)	n = 146,050	n = 58,112
- Lower	43,750 (30%)	16,359
- Moderate	57,785 (40%)	23,770
- Higher	44,515 (30%)	17,983
Body mass index	26.05 (4.34) n = 147,719	25.81 (4.27) n = 58,680
RFFT (Unique designs) [Mean ( <i>SD</i> )]	81.50 (22.94) n = 88,096	82.46 (23.01) n = 36,563
Any Depressive Disorder (Current Major Depression or Dysthymia)	3.4% n = 141,045	2.9% n = 56,861
Major Depressive Episode (Current)	2.1% n = 141,538	1.8% n = 57,048
Any Anxiety Disorder (panic disorder, agoraphobia, social phobia, or GAD )	7.8% n = 141,538	7.2% n = 57,048
Generalized Anxiety Disorder	4.2% n = 141,539	3.8% n = 57,048
Negative Affect Score [Mean ( <i>SD</i> )]	20.71 (13.12)	20.70 (5.22)

	n = 139,217	n = 57,964
Positive Affect Score [Mean (SD)]	35.37 (4.25)	35.37 (4.19)
	n = 139,217	n = 57,964
C-reactive protein level (mg/L), [Median (IQR), Mean (SD)]	1.2 (.60, 2.80), 2.61 (4.76)	1.2 (2.2) 2.62 (4.60)
	n = 55,098	n = 23,607
<b>First follow up</b>		
Any Depressive Disorder (Current Major Depression or Dysthymia)	4.1% n = 77,758	Not used
Major Depressive Episode (Current)	3.0% n = 77,758	Not used
Any Anxiety Disorder (panic disorder, agoraphobia, social phobia, or GAD )	8.3% n = 77,758	Not used
Generalized Anxiety Disorder	5.9% n = 77,758	Not used
Cogstate: Episodic Memory (Accuracy), Mean (SD)	0.96 (0.12) n = 84,819	0.96 (0.12) n = 36,798
Cogstate: Working Memory (Accuracy), Mean (SD)	1.31 (0.19) n = 83,721	1.32 (0.19) n = 36,363
Cogstate: Visual Attention (Response Time), Mean (SD)	2.69 (0.09) n = 82,175	2.68 (0.09) n = 35,743
Cogstate: Psychomotor Speed (Response Time), Mean (SD)	2.56 (0.16) n = 81,139	2.55 (0.16) n = 35,314
Lower = no education, primary education, lower/preparatory vocational education, lower general secondary education; Moderate = intermediate vocational education/apprenticeship, higher secondary education; Higher = higher vocational education, university; IQR = Inter Quartile Range.		

**Table 3. Bivariate Correlations of Study Variables for 147,815 Participants**

Measure	2.	3.	4.	5.	6.	7.	8.	9.	10.	11.	12.	13.	14.	15.	16.	17.	18.	19.	20.	21.
1. T1 CRP (log-transformed)	-0.03	-0.03	0.04	0.03	-0.07	0.04	0.03	0.03	-0.05	0.03	0.14	0.11	0.36	0.10	0.03	0.03	0.03	0.03	0.02	0.03
2. T2 Episodic Memory <sup>B</sup>	-	0.31	-0.16	-0.16	0.21	-0.02	-0.03	-0.05	-0.02	-0.19	0.01	0.22	-0.08	-0.04	-0.02	-0.01	-0.03	-0.03	-0.01	-0.01
3. T2 Working Memory <sup>B</sup>		-	-0.17	-0.17	0.20	-0.02	-0.02	-0.04	.00 <sup>a</sup>	-0.20	-.01 <sup>a</sup>	-0.2	-0.07	-0.04	-0.02	0	-0.03	-0.02	-0.01	-0.01
4. T2 Psychomotor Speed <sup>C</sup>			-	0.63	-0.30	.01 <sup>a</sup>	.00 <sup>a</sup>	0.04	.00 <sup>a</sup>	0.39	.00 <sup>a</sup>	0.21	0.08	0.04	0.01	-0.02	0.01	0	-0.01	-0.02
5. T2 Visual Attention <sup>C</sup>				-	-0.34	0.01	.00 <sup>a</sup>	0.05	-0.02	0.43	-0.01	0.20	0.09	0.05	0.02	-0.01	0.02	0.01	0.01	-0.01
6. T1 RFFT					-	-0.04	-0.02	-0.07	-0.07	-0.32	0.03	-0.35	-0.11	-0.08	-0.04	-0.01	-0.04	-0.02	-0.02	0.01
7. T1 Depression						-	0.25	0.27	-0.2	-0.02	0.05	0.07	0.04	0.07	0.35	0.19	0.8	0.21	0.40	0.18
8. T2 Depression							-	0.21	-0.13	-0.05	0.03	0.05	0.03	0.05	0.20	0.41	0.22	0.83	0.21	0.42
9. T1 Negative Affect								-	-0.21	-0.05	0.17	0.08	-0.01	0.06	0.32	0.26	0.25	0.17	0.30	0.22
10. T1 Positive Affect									-	-0.02	-0.01	-0.1	-0.02	-0.02	-0.17	-0.13	-0.18	-0.1	-0.18	-0.11
11. T1 Age										-	-0.04	0.23	0.19	0.09	-0.01	-0.06	-0.01	-0.04	-0.04	-0.06
12. T1 Female											-	0.02	-0.06	0.03	0.07	0.07	0.04	0.03	0.05	0.06
13. T1 Education												-	0.17	0.08	0.06	0.03	0.07	0.05	0.04	0.02
14. T1 Body mass index													-	0.13	0.03	0.01	0.04	0.03	0.02	0.01
15. T1 Health Status														-	0.07	0.04	0.06	0.05	0.05	0.04
16. T1 ANX															-	0.28	0.31	0.17	0.72	0.2
17. T2 ANX																-	0.17	0.37	0.22	0.84
18. T1 MDE																	-	0.20	0.38	0.16
19. T2 MDE																		-	0.17	0.40
20. T1 GAD																			-	0.21
21. T2 GAD																				-

Probability <sup>a</sup> =  $P > .05$ ; <sup>B</sup> = higher values equal better performance; <sup>C</sup> = higher values equal poorer performance; T1 = Time 1 (Baseline); T2 = Time 2 (First Follow-up); RFFT = Ruff Figural Fluency Test; Health Status. = Number of Medical Conditions Reported; for values  $\leq .001$  and  $\geq -.001$ , values were rounded to 0.

**Table 4. Associations of CRP levels with affect, depressive and anxiety disorders, and cognitive task performance in the Lifelines cohort**

Please note: point estimates do not include 95% confidence intervals (and N, p-value) as we do not currently have access to the Lifelines Cohort Workspace, the Cohort will allow us access to data for response to reviewer comments, we will add these (p-value, 95% CI, N) as necessary during review.

Predictors	Baseline							Follow-up							
	MDD	Any DEP	GAD	Any ANX	Negative Affect	Positive Affect	RFFT	MDD	Any DEP	GAD	Any ANX	Psycho motor Speed	Attention	Episodic Memory	Working Memory
	Odd's Ratio				Standardized regression coefficient			Odd's Ratio				Standardized regression coefficient			
<b>Model 1 (Unadjusted analysis)</b>															
CRP <sup>a</sup>	1.59	1.57	1.24	1.29	.03	-.05	-.07	1.43	1.42	1.26	1.22	.03	.03	-.03	-.03
<b>Model 2 (Adjusted for age, sex, education, health status, and BMI)</b>															
CRP <sup>a</sup>	1.02†	1.22	1.01†	1.06†	.01	-.04	-.03	1.06†	1.07†	1.05†	1.03†	.01	.01	0†	-.01†
Age	.98	.98	.98	.99	-.06	0†	-.24	.97	.97	.97	.98	.38	.38	-.14	-.17
Female	1.53	1.59	1.56	1.66	.17	0†	.04	1.28	1.33	1.58	1.6	.01†	.01†	0†	-.01
Education: High	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Education: Moderate	1.62	1.76	1.3	1.28	.04	-.04	-.19	1.39	1.31	1.1†	1.12	.07	.07	-.13	-.08
Education: Low	2.94	3.02	1.64	1.72	.11	-.11	-.35	2.16	1.84	1.26	1.3	.16	.16	-.22	-.18
Health Status: 0 Dx	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Health Status: 1 Dx	1.83	1.64	1.55	1.43	.04	-.01	-.02	1.5	1.5	1.36	1.29	0†	0†	0†	-.01†
Health Status: 2 Dx	2.97	2.63	2.26	1.82	.04	0†	-.02	2.5	2.34	1.67	1.47	0†	0†	-.01	-.02
Health Status: 3+ Dx	4.24	3.76	2.82	2.65	.02	-.01	-.01	3.71	3.28	2	1.67	0†	0†	-.01	0†
BMI	1.04	1.03	1.01	1.01	0†	0†	0†	1.05	1.04	1.02	1.02	0†	0†	-.03	-.01†

CRP = C-reactive Protein; MDD = Major Depressive Disorder; Any DEP = MDD or Dysthymia; GAD = Generalized Anxiety Disorder; Any ANX = panic disorder, agoraphobia,

social phobia, or GAD; RFFT = Ruff Figural Fluency Test; <sup>a</sup> = log-transformed variable; BMI = Body Mass Index; Ref = Reference Category for categorical variables; † =  $p > .05$ ;  
Odds ratios are reported in logistic regression predicting binary outcomes and standardized beta coefficients are reported for linear regression; For values  $\leq .001$  and  $\geq -.001$ ,  
values were rounded to 0.